Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Set Alert for Commercial

Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise

SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.

Clinical Trials Infectious Diseases Gastrointestinal

Vasopharm Sees Path Forward For Traumatic Brain Injury Drug

Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.

Neurology Clinical Trials Research & Development

Companies

Set Alert for Companies

Latest From Companies

Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval

Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.

Approvals Safety

Boehringer Buys Abexxa To Boost Cancer Pipeline

The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.

M & A ImmunoOncology

Publisher's Spotlight: Scrip Awards Announces 2021 Finalists

We are delighted to announce the shortlist for the 17th Annual Scrip Awards.

Companies Commercial

BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals

Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.

Companies StartUps and SMEs

New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.

Commercial Companies

Novartis Doubles Up In Optogenetics With Arctos Buy

The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.

M & A Gene Therapy
See All

Deals

Set Alert for Deals

Latest From Deals

Boehringer Buys Abexxa To Boost Cancer Pipeline

The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.

M & A ImmunoOncology

Vifor Clinches Deal For Travere's Rare Kidney Disorder Drug

The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.

Renal Deals

Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal

Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.

China Deals

Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave

Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.

Deal Watch Deals

AbbVie Extends Reach Of Regenxbio’s Wet AMD Program

The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.

Deals Gene Therapy

Merck KGaA In The Market For Bolt-On M&A

Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."

M & A Strategy
See All

Strategy

Set Alert for Strategy

Latest From Strategy

Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC

Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.

Clinical Trials Strategy

Bayer Bigs Up Vitrakvi In Comparison With Roche's Rozlytrek

In the absence of head-to-head data, the results from a "matching-adjusted indirect comparison" suggest favorable efficacy of the German group's treatment for solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion when compared with competitor Rozlytrek from Roche.

Cancer Clinical Trials

First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC

Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.

Clinical Trials Personalized Medicine

Amylyx Will Submit ALS Drug For Approval In The Coming Months

After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.

Drug Approval Standards Neurology

Working Toward A Cure: Janssen’s Multiple Myeloma Strategy

Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.

Strategy Clinical Trials

Merck KGaA In The Market For Bolt-On M&A

Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."

M & A Strategy
See All

Market Access

Set Alert for Market Access

Latest From Market Access

All Systems Go For Novartis 'World-First' Leqvio Pact With England

A price has finally been agreed for Novartis's small interfering RNA therapy and over the next three years, NHS England now expects to treat about 300,000 patients at high risk of a second cardiovascular event with inclisiran.

Cardiovascular Market Access

The Booming Business Of Drug Exclusions

The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.

Market Access Reimbursement

Podcast: What's Ahead For Aduhelm's Launch And Reimbursement

Scrip and Pink Sheet editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.

Neurology Launches
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Wet AMD Market Snapshot: A High-Growth Market Poised For Change

Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.

Ophthalmic Market Snapshot

BI/Lilly's Jardiance Enters US Heart Failure Market Fray

Boehringer Ingelheim and Eli Lilly have gained a US approval for their SGLT2 inhibitor empagliflozin in heart failure with reduced ejection fraction, which could be extended further in coming months to other types of heart failure, adding to the products competing in this previously neglected therapeutic area.

Approvals Cardiovascular

Beckley Psytech To Evaluate Psilocybin In A Rare Debilitating Headache

The effect of low-dose psilocybin, a compound found in mushrooms, on a rare debilitating condition, short-lasting unilateral neuralgiform headaches attacks, is to be evaluated by the 2019-founded UK biotech, Beckley Psytech.

Neurology Rare Diseases
See All
UsernamePublicRestriction

Register